Advertisement

Phytochemistry Reviews

, Volume 13, Issue 3, pp 717–724 | Cite as

Novel antitumor mechanisms of curcumin: implication of altered tumor metabolism, reconstituted tumor microenvironment and augmented myelopoiesis

  • Naveen Kumar Vishvakarma
Article

Abstract

Curcumin, a product of turmeric plant (Curcuma longa), is widely recognized for its antitumor and anti-inflammatory actions. Multiple mechanisms mediate the antitumor actions of curcumin, involving modulation of cell signaling events, manifesting tumor cytostasis and cytotoxicity. However, until recent it was unclear if the antitumor actions of curcumin also implicate modulation of some crucial checkpoints of unique tumor-specific metabolic events and tumor growth regulatory components of tumor microenvironment (TME), which are the focus of emerging antitumor therapeutic strategies. Considering the indispensible role of these hallmarks of cancer in tumor progression, recent studies investigated if curcumin could also therapeutically target one or more of these driving forces of oncogenesis. Investigations strongly indicate that curcumin can alter glucose uptake and its metabolism in tumor cells, leading to an altered pH homeostasis and reversal of lactic acidosis, culminating in induction of apoptosis. Curcumin can also inhibit tumor progression by antagonizing pro-inflammatory cellular and biophysical parameters of TME. Further, curcumin exerts myelopoietic action, owing to the withdrawal of tumor-dependent toxicity and myelosuppression, improved expression of heme-oxygenase and alleviation of the inhibitory actions of anticancer drugs on bone marrow cells. This review compiles the present state of knowledge, with respect to the effect of this wonder drug on tumor metabolism, components of TME and myelopoiesis. The review also predicts the possible impact of these newly understood roles of curcumin in designing of novel therapeutic protocols against cancer.

Keywords

Curcumin Anti-tumor Tumor metabolism Myelopoiesis Macrophage differentiation Tumor microenvironment 

Notes

Acknowledgments

The author is grateful to the Department of Botany and Microbiology, HNB Garhwal University, India for facilities required for preparing this manuscript.

References

  1. Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23:363–398PubMedGoogle Scholar
  2. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Tharakan ST, Sung B, Anand P (2008) Potential of spice-derived phytochemicals for cancer prevention. Planta Med 74:1560–1569PubMedCrossRefGoogle Scholar
  3. Aggarwal BB, Van Kuiken ME, Iyer LH, Harikumar KB, Sung B (2009) Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. Exp Biol Med 234:825–849CrossRefGoogle Scholar
  4. Aggarwal BB, Yuan W, Li S, Gupta SC (2013) Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: identification of novel components of turmeric. Mol Nutr Food Res 57:1529–1542PubMedCrossRefGoogle Scholar
  5. Agrawal DK, Mishra PK (2010) Curcumin and its analogues: potential anticancer agents. Med Res Rev 30:818–860PubMedGoogle Scholar
  6. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4:807–818PubMedCrossRefGoogle Scholar
  7. Asher GN, Spelman K (2013) Clinical utility of curcumin extract. Altern Ther Health Med 19:20–32PubMedGoogle Scholar
  8. Baniyash M, Sade-Feldman M, Kanterman J (2013) Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother (Epub ahead of print)Google Scholar
  9. Bayet-Robert M, Morvan D (2013) Metabolomics reveals metabolic targets and biphasic responses in breast cancer cells treated by curcumin alone and in association with docetaxel. PLoS ONE 8(3):e57971PubMedCentralPubMedCrossRefGoogle Scholar
  10. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C et al (2010) Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9:8–14PubMedCrossRefGoogle Scholar
  11. Bisht K, Choi WH, Park SY, Chung MK, Koh WS (2009) Curcumin enhances non-inflammatory phagocytic activity of RAW264.7 cells. Biochem Biophys Res Commun 379:632–636PubMedCrossRefGoogle Scholar
  12. Cairns R, Papandreou I, Denko N (2006) Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4:61–70PubMedCrossRefGoogle Scholar
  13. Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G (2013) Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol 23:522-532Google Scholar
  14. Chang YF, Chuang HY, Hsu CH, Liu RS, Gambhir SS, Hwang JJ (2012) Immunomodulation of curcumin on adoptive therapy with T cell functional imaging in mice. Cancer Prev Res 5:444–452CrossRefGoogle Scholar
  15. Chen CC, Sureshbabul M, Chen HW, Lin YS, Lee JY, Hong QS, et al. (2013) Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer. Evid Based Complement Alternat Med 2013:541695Google Scholar
  16. Chiu M, Ottaviani L, Bianchi MG, Franchi-Gazzola R, Bussolati O (2012) Towards a metabolic therapy of cancer? Acta Biomed 83:168–176PubMedGoogle Scholar
  17. Choi H, Chun YS, Kim SW, Kim MS, Park JW (2006) Curcumin inhibits hypoxia- inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol 70:1664–1671PubMedCrossRefGoogle Scholar
  18. Coimbra M, Isacchi B, van Bloois L, Torano JS, Ket A, Wu X et al (2011) Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int J Pharm 416:433–442PubMedGoogle Scholar
  19. Darvesh AS, Aggarwal BB, Bishayee A (2012) Curcumin and liver cancer: a review. Curr Pharm Biotechnol 13:218–228PubMedCrossRefGoogle Scholar
  20. Draghiciu, O, Nijman, HW, Daemen, T (2011) From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol 2011:439053Google Scholar
  21. Fang HY, Chen SB, Guo DJ, Pan SY, Yu ZL (2011) Proteomic identification of differentially expressed proteins in curcumin-treated MCF-7 cells. Phytomedicine 18:697–703PubMedCrossRefGoogle Scholar
  22. Ford NA, Lashinger LM, Allott EH, Hursting SD (2013) Mechanistic targets and phytochemical strategies for breaking the obesity-cancer link. Front Oncol 3:209PubMedCentralPubMedCrossRefGoogle Scholar
  23. Fraser ST, Midwinter RG, Berger BS, Stocker R (2011) Heme oxygenase-1: a critical link between iron metabolism, erythropoiesis, and development. Adv Hematol 2011:473709. doi: 10.1155/2011/473709 PubMedCentralPubMedGoogle Scholar
  24. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174PubMedCentralPubMedGoogle Scholar
  25. Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14:1014–1022PubMedCentralPubMedCrossRefGoogle Scholar
  26. Gerhauser C (2013) Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. Top Curr Chem 329:73–132PubMedCrossRefGoogle Scholar
  27. Ghiringhelli F, Rebe C, Hichami A, Delmas D (2012) Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents. Anticancer Agents Med Chem 12:852–873PubMedCrossRefGoogle Scholar
  28. Goel A, Aggarwal BB (2010) Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62:919–930PubMedCrossRefGoogle Scholar
  29. Gonda TA, Tu S, Wang TC (2009) Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 8:2005–2013PubMedCrossRefGoogle Scholar
  30. Gostner J, Ciardi C, Becker K, Fuchs D, Sucher R (2014) Immunoregulatory impact of food antioxidants. Curr Pharm Des 20:840–849Google Scholar
  31. Gu Q, Cai Y, Huang C, Shi Q, Yang H (2012) Curcumin increases rat mesenchymal stem cell osteoblast differentiation but inhibits adipocyte differentiation. Pharmacogn Mag 8:202–208PubMedCentralPubMedCrossRefGoogle Scholar
  32. Gupta SC, Kismali G, Aggarwal BB (2013a) Curcumin, a component of turmeric: from farm to pharmacy. BioFactors 39:2–13PubMedCrossRefGoogle Scholar
  33. Gupta SC, Patchva S, Aggarwal BB (2013b) Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15:195–218PubMedCentralPubMedCrossRefGoogle Scholar
  34. Hagemann T, Balkwill F, Lawrence T (2007) Inflammation and cancer: a double-edged sword. Cancer Cell 12:300–301PubMedCentralPubMedCrossRefGoogle Scholar
  35. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674PubMedCrossRefGoogle Scholar
  36. Hasima N, Aggarwal BB (2014) Targeting proteasomal pathways by dietary curcumin for cancer prevention and treatment. Curr Med Chem 21(14):1583–94Google Scholar
  37. Hu L, Jia Y, Niu F, Jia Z, Yang X, Jiao K (2012) Preparation and enhancement of oral bioavailability of curcumin using microemulsions vehicle. J Agric Food Chem 60:7137–7141PubMedCrossRefGoogle Scholar
  38. Jagetia GC, Aggarwal BB (2007) “Spicing up” of the immune system by curcumin. J Clin Immunol 27:19–35PubMedCrossRefGoogle Scholar
  39. Kaefer CM, Milner JA (2008) The role of herbs and spices in cancer prevention. J Nutr Biochem 19:347–361PubMedCentralPubMedCrossRefGoogle Scholar
  40. Kaefer CM, Milner JA (2011) Herbs and spices in cancer prevention and treatment. In: Benzie IFF, Wachtel-Galor S (eds) Herbal medicine: biomolecular and clinical aspects, 2nd edn. CRC Press, Boca Raton, FL (Chapter 17)Google Scholar
  41. Kappler M, Taubert H, Schubert J, Vordermark D, Eckert AW (2012) The real face of HIF1α in the tumor process. Cell Cycle 11:3932–3936PubMedCentralPubMedCrossRefGoogle Scholar
  42. Kareva I, Hahnfeldt P (2013) The emerging “hallmarks” of metabolic reprogramming and immune evasion: distinct or linked? Cancer Res 73:2737–2742PubMedCrossRefGoogle Scholar
  43. Kaushik G, Kaushik T, Yadav SK, Sharma SK, Ranawat P, Khanduja KL et al (2012) Curcumin sensitizes lung adenocarcinoma cells to apoptosis via intracellular redox status mediated pathway. Indian J Exp Biol 50:853–861PubMedGoogle Scholar
  44. Kawakami Y, Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Iwata-Kajihara T et al (2013) Cancer-induced immunosuppressive cascades and their reversal by molecular-targeted therapy. Ann N Y Acad Sci 1284:80–86PubMedCrossRefGoogle Scholar
  45. Kou MC, Chiou SY, Weng CY, Wang L, Ho CT, Wu MJ (2013) Curcuminoids distinctly exhibit antioxidant activities and regulate expression of scavenger receptors and heme oxygenase-1. Mol Nutr Food Res 57:1598–1610PubMedCrossRefGoogle Scholar
  46. Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269:199–225PubMedCrossRefGoogle Scholar
  47. Liu D, Chen Z (2013) The effect of curcumin on breast cancer cells. J Breast Cancer 16:133–137PubMedCentralPubMedCrossRefGoogle Scholar
  48. Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P (2013) Harnessing the power of the immune system to target cancer. Annu Rev Med 64:71–90PubMedCrossRefGoogle Scholar
  49. Lu H, Ouyang W, Huang C (2006) Inflammation, a key event in cancer development. Mol Cancer Res 4:221–233PubMedCrossRefGoogle Scholar
  50. Luo F, Song X, Zhang Y, Chu Y (2011) Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity. Int Immunopharmacol 11:1234–1240PubMedCrossRefGoogle Scholar
  51. Mantovani A, Locati M (2013) Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol 33:1478–1483PubMedCrossRefGoogle Scholar
  52. Monteleone G, Pallone F, Stolfi C (2012) The dual role of inflammation in colon carcinogenesis. Int J Mol Sci 13:11071–11084PubMedCentralPubMedCrossRefGoogle Scholar
  53. Monti E, Gariboldi MB (2011) HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr Mol Pharmacol 4:62–77PubMedCrossRefGoogle Scholar
  54. Nagaraju GP, Zhu S, Wen J, Farris AB, Adsay VN, Diaz R, et al. (2013) Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett 341:195–203Google Scholar
  55. Norris L, Karmokar A, Howells L, Steward WP, Gescher A, Brown K (2013) The role of cancer stem cells in the anti-carcinogenicity of curcumin. Mol Nutr Food Res 57:1630–1637PubMedCrossRefGoogle Scholar
  56. Pal S, Bhattacharyya S, Choudhuri T, Datta GK, Das T, Sa G (2005) Amelioration of immune cell number depletion and potentiation of depressed detoxification system of tumor-bearing mice by curcumin. Cancer Detect Prev 29:470–478PubMedCrossRefGoogle Scholar
  57. Papież MA (2013) The influence of curcumin and (−)-epicatechin on the genotoxicity and myelosuppression induced by etoposide in bone marrow cells of male rats. Drug Chem Toxicol 36:93–101PubMedCrossRefGoogle Scholar
  58. Park W, Amin AR, Chen ZG, Shin DM (2013) New perspectives of curcumin in cancer prevention. Cancer Prev Res 6:387–400CrossRefGoogle Scholar
  59. Parks SK, Chiche J, Pouysségur J (2013) Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer 13:611–623PubMedCrossRefGoogle Scholar
  60. Prasad S, Tyagi AK, Aggarwal BB (2014) Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat 46:2–18PubMedCentralPubMedCrossRefGoogle Scholar
  61. Priyadarsini KI (2013) Chemical and structural features influencing the biological activity of curcumin. Curr Pharm Des 19:2093–2100PubMedGoogle Scholar
  62. Qiu P, Xu L, Gao L, Zhang M, Wang S, Tong S et al (2013) Exploring pyrimidine-substituted curcumin analogues: design, synthesis and effects on EGFR signaling. Bioorg Med Chem 21:5012–5020PubMedCrossRefGoogle Scholar
  63. Qu W, Xiao J, Zhang H, Chen Q, Wang Z, Shi H et al (2013) B19, a Novel monocarbonyl analogue of curcumin, induces human ovarian cancer cell apoptosis via activation of endoplasmic reticulum stress and the autophagy signaling pathway. Int J Biol Sci 9:766–777PubMedCentralPubMedCrossRefGoogle Scholar
  64. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267–296PubMedCentralPubMedCrossRefGoogle Scholar
  65. Ravindran J, Subbaraju GV, Ramani MV, Sung B, Aggarwal BB (2010) Bisdemethylcurcumin and structurally related hispolon analogues of curcumin exhibit enhanced prooxidant, anti-proliferative and anti-inflammatory activities in vitro. Biochem Pharmacol 79:1658–1666PubMedCentralPubMedCrossRefGoogle Scholar
  66. Roberts NJ, Zhou S, Diaz LA Jr, Holdhoff M (2011) Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2:739–751PubMedCentralPubMedGoogle Scholar
  67. Ruggiero L, Sogno I, Focaccetti C, Bartolini D, Magnani E, Principi E, Noonan DM, Albini A (2012) Effects of diet-derived molecules on the tumor microenvironment. Current Angiogenesis 1:206–214CrossRefGoogle Scholar
  68. Saeidnia S, Abdollahi M (2013) Antioxidants: friends or foe in prevention or treatment of cancer: the debate of the century. Toxicol Appl Pharmacol 271:49–63PubMedCrossRefGoogle Scholar
  69. Santel T, Pflug G, Hemdan NY, Schäfer A, Hollenbach M, Buchold M et al (2008) Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity. PLoS ONE 3(10):e3508PubMedCentralPubMedCrossRefGoogle Scholar
  70. Semenza GL (2013) HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123:3664–3671PubMedCentralPubMedCrossRefGoogle Scholar
  71. Shahani K, Panyam J (2011) Highly loaded, sustained-release microparticles of curcumin for chemoprevention. J Pharm Sci 110:2599–2609CrossRefGoogle Scholar
  72. Shehzad A, Wahid F, Lee YS (2010) Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm 343:489–499CrossRefGoogle Scholar
  73. Shishodia S (2013) Molecular mechanisms of curcumin action: gene expression. BioFactors 39:37–55PubMedCrossRefGoogle Scholar
  74. Shishodia S, Chaturvedi MM, Aggarwal BB (2007) Role of curcumin in cancer therapy. Curr Probl Cancer 31:243–305PubMedCrossRefGoogle Scholar
  75. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787–795PubMedCentralPubMedCrossRefGoogle Scholar
  76. Sinha D, Biswas J, Sung B, Aggarwal BB, Bishayee A (2012) Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr Drug Targets 13:1799–1819PubMedCrossRefGoogle Scholar
  77. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A et al (2011) A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 118:2254–2265PubMedCentralPubMedCrossRefGoogle Scholar
  78. Subramaniam D, Ponnurangam S, Ramamoorthy P, Standing D, Battafarano RJ, Anant S et al (2012) Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS ONE 7(2):e30590PubMedCentralPubMedCrossRefGoogle Scholar
  79. Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G, Liu A, Wang TC, Yang CS (2012) Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res 5:205–215CrossRefGoogle Scholar
  80. Tuttle S, Hertan L, Katz JS (2011) Indian gold treating cancer in the age of nano. Cancer Biol Ther 11:474–476PubMedCrossRefGoogle Scholar
  81. Vaughan RA, Garcia-Smith R, Dorsey J, Griffith JK, Bisoffi M, Trujillo KA (2013) Tumor necrosis factor alpha induces Warburg-like metabolism and is reversed by anti-inflammatory curcumin in breast epithelial cells. Int J Cancer 133:2504–2510PubMedCrossRefGoogle Scholar
  82. Vishvakarma NK, Singh SM (2010) Immunopotentiating effect of proton pump inhibitor pantoprazole in a lymphoma-bearing murine host: implication in antitumor activation of tumor-associated macrophages. Immunol Lett 134:83–92PubMedCrossRefGoogle Scholar
  83. Vishvakarma NK, Singh SM (2011) Augmentation of myelopoiesis in a murine host bearing a T cell lymphoma following in vivo administration of proton pump inhibitor pantoprazole. Biochimie 93:1786–1796PubMedCrossRefGoogle Scholar
  84. Vishvakarma NK, Kumar A, Singh SM (2011) Role of curcumin-dependent modulation of tumor microenvironment of a murine T cell lymphoma in altered regulation of tumor cell survival. Toxicol Appl Pharmacol 252:298–306PubMedCrossRefGoogle Scholar
  85. Vishvakarma NK, Kumar A, Kumar A, Kant S, Bharti AC, Singh SM (2012) Myelopotentiating effect of curcumin in tumor-bearing host: role of bone marrow resident macrophages. Toxicol Appl Pharmacol 263:111–121PubMedCrossRefGoogle Scholar
  86. Yadav SK, Sah AK, Jha RK, Sah P, Shah DK (2013) Turmeric (curcumin) remedies gastroprotective action. Pharmacogn Rev 7:42–46PubMedCentralPubMedCrossRefGoogle Scholar
  87. Yallapu MM, Ebeling MC, Jaggi M, Chauhan SC (2013) Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics. Curr Drug Metab 14:504–515PubMedCentralPubMedCrossRefGoogle Scholar
  88. Yang C, Su X, Liu A, Zhang L, Yu A, Xi Y et al (2013a) Advances in clinical study of curcumin. Curr Pharm Des 19:1966–1973PubMedGoogle Scholar
  89. Yang CH, Yue J, Sims M, Pfeffer LM (2013b) The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo. PLoS ONE 8:e71130PubMedCentralPubMedCrossRefGoogle Scholar
  90. Yin HT, Zhang DG, Wu XL, Huang XE, Chen G (2013) In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. Asian Pac J Cancer Prev 14:409–412PubMedCrossRefGoogle Scholar
  91. Zaidi MR, Merlino G (2011) The two faces of interferon-γ in cancer. Clin Cancer Res 17:6118–6124PubMedCentralPubMedCrossRefGoogle Scholar
  92. Zamarron BF, Chen W (2011) Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 7:651–658PubMedCentralPubMedCrossRefGoogle Scholar
  93. Zhang Q, Zhong Y, Yan LN, Sun X, Gong T, Zhang ZR (2011) Synthesis and preliminary evaluation of curcumin analogues as cytotoxic agents. Bioorg Med Chem Lett 21:1010–1014PubMedCrossRefGoogle Scholar
  94. Zhao C, Cai Y, He X, Li J, Zhang L, Wu J et al (2010) Synthesis and anti-inflammatory evaluation of novel mono-carbonyl analogues of curcumin in LPS-stimulated RAW 264.7 macrophages. Eur J Med Chem 45:5773–5780PubMedCrossRefGoogle Scholar
  95. Zlotogorski A, Dayan A, Dayan D, Chaushu G, Salo T, Vered M (2013) Nutraceuticals as new treatment approaches for oral cancer—I: curcumin. Oral Oncol 49:187–191PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Department of BiotechnologyGuru Ghasidas VishwavidyalayaKoni, BilaspurIndia

Personalised recommendations